Navigation Links
ResearchDx and Menarini Silicon Biosystems Launch DEPArray HER2 for Breast and GEA Cancers
Date:10/5/2017

ResearchDx, the leading biopharma companion diagnostics provider and Menarini Silicon Biosystems, worldwide manufacturer of image-based cell sorting products and services, jointly announce the launch of DEPArray HER2. The fluorescence in situ hybridization (FISH)-based assay has been validated as a clinical research laboratory developed test (LDT) and is performed by PacificDx, a CAP/CLIA certified and wholly owned subsidiary laboratory of ResearchDx.

Close to 300,000 breast and gastroesophageal adenocarcinoma (GEA) tumors are diagnosed each year in the United States. An estimated 20% of those tumors harbor HER2 gene amplifications. Accurate assessment of HER2 status in breast and GEA cancers is critical for identifying patients predicted to respond to anti-HER2 targeted therapies. Traditional tissue-based assessment of HER2 gene status can be problematic due the mixture of tumor and stromal (normal) tissue in a standard biopsy sample. Compounding the problem of tissue heterogeneity is the known intra-tumor genetic heterogeneity of many breast and GEA cancers such that only a small percentage of the tumor contains HER2 gene amplification.

The DEPArray HER2 test leverages cell isolation capabilities of DEPArray™ NxT technology allowing isolation of pure tumor cell populations from heterogeneous tumor/normal tissue samples. The HER2 test is performed on pure tumor populations isolated from stained cell suspensions digitally sorted using the DEPArray NxT, thus eliminating tissue heterogeneity and allowing true genetic heterogeneity to be revealed more accurately.

“We are the first clinical laboratory to offer HER2 gene testing on pure cell populations isolated from tumor tissue by DEPArray NxT technology,” said Shelly Gunn MD, PhD. ResearchDx’s Chief Medical Officer and Medical Director of the PacificDx clinical laboratory. “We are looking forward to validating additional applications for DEPArray NxT technology including isolation of circulating tumor cells (CTCs) for liquid biopsy applications in a variety of solid tumors.”

“We are excited to see the launch our first DEPArray NxT-based clinical test in the U.S. Notably, this will provide physicians, and most importantly their patients, access to a solution in overcoming unresolved/equivocal HER2 status observed with tissue biopsies“ said Farideh Bischoff, PhD. Menarini Silicon Biosystems, Inc. Chief Clinical Development Officer.

The DEPArray HER2 test has a 5-7 day turn around time and can be performed in our CAP/CLIA certified laboratory on any archival tumor tissue sample. For more information about the test, please visit: http://www.pacificdx.com.

Read the full story at http://www.prweb.com/releases/2017/10/prweb14765621.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. ResearchDx Appointment of New Chief Medical Officer to Meet NIH Push for Precision Medicine in Expediting Bench to Bedside" Strategies for Disease Treatment
2. ResearchDx and BioSmartSA Announce New Consulting Practice in Saudi Arabia
3. ResearchDx/PacificDx to Present High-Resolution HER2 Testing Data at the San Antonio Breast Cancer Symposium
4. Menarini and Meyer United In The Search For Rare Cells
5. Building quantum states with individual silicon atoms
6. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
7. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
8. MarketPublishers.com Added New Report on Silicon Tetrafluoride (CAS 7783-61-1) Market to Its Catalogue
9. NASA Scientists and Silicon Valley Space Center Partners Make Home Team Bid for Moffett Federal Airfield Development
10. MarketPublishers.com Added New Report on Silicon Nitride (CAS 12033-89-5) Market to Its Catalogue
11. Brainwave Signal Interpretation Software Company EyeMynd Announces Move to Silicon Valley
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2019)... , ... January 29, 2019 , ... ... (AskBio), today announced the dosing of the first patient in a phase 1/2 ... a serious disease associated with high morbidity and often leads to premature death. ...
(Date:1/30/2019)... ... January 30, 2019 , ... ... the international tasting 5StarWines to promote and give recognition to producers whose work ... Without Walls selection takes place in Verona, Italy, contemporaneously to the 5StarWines blind ...
(Date:1/24/2019)... ... January 23, 2019 , ... Through its ... research support in study design, planning, sample collection, and analysis to researchers at ... Campus in Trinidad led by Dr. Elaine Monica Davis, MBBS, MPhil, Lecturer of ...
(Date:1/20/2019)... (PRWEB) , ... January 17, 2019 , ... ... Autodesk Platinum Partner announces the launch of a specialized automation technology, titled Automate ... parameters for automatic generation of models and drawings to deliver to end-users, customers, ...
Breaking Biology Technology:
(Date:2/6/2019)... ... 2019 , ... uBiome, the leader microbial genomics, announced today ... understand how the gut microbes may increase the risk of arterial plaque buildup ... contain choline and L-carnitine, such as red meat and eggs, various gut microbes ...
(Date:2/2/2019)... ... 2019 , ... Through its Microbiome Grant Initiative , ... design, planning, sample collection, and analysis to researchers at Stanford University led by ... Vaughn, MD, Reproductive Endocrinology and Infertility Fellow, to study the role of abnormal ...
(Date:1/30/2019)... ... January 30, 2019 , ... ... life science and biotechnology companies, announced today that it will host a ... venture funds to discuss their investment philosophies, explain their fund and deal ...
Breaking Biology News(10 mins):